Breadcrumb

Lea C. Cunningham, M.D.

Lea C. Cunningham, M.D.

  • Center for Cancer Research
  • National Cancer Institute
Immune Deficiency Cellular Therapy Program

RESEARCH SUMMARY

Dr. Cunningham is developing clinical protocols for the prevention and treatment of hematologic malignancies associated with deleterious germline RUNX1 variants. Dr. Cunningham is also Director of the NIH Pediatric Bone Marrow Transplantation Fellowship Program. 

Areas of Expertise

RUNX1 Deficiency
Pediatric HSCT
Myelodysplastic Syndrome
Myeloid Malignancies

Information for Patients

Learn more about our clinical trials and the highly specialized care teams that lead them.

Publications

Selected Publications

Acute Kidney Injury in Pediatric Patients Receiving Allogeneic Hematopoietic Cell Transplantation: Incidence, Risk Factors, and Outcomes

Koh KN, Sunkara A, Kang G, Sooter A, Mulrooney DA, Triplett B, Onder AM, Bissler J, Cunningham LC.
Biol Blood Marrow Transplant. 24(4): 758-764, 2018. [ Journal Article ]

Selective T-cell depletion targeting CD45RA reduces viremia and enhances early T-cell recovery compared with CD3-targeted T-cell depletion

Triplett BM, Muller B, Kang G, Li Y, Cross SJ, Moen J, Cunningham L, Janssen W, Mamcarz E, Shook DR, Srinivasan A, Choi J, Hayden RT, Leung W.
Transpl Infect Dis. 20(1): e12823, 2018. [ Journal Article ]

An overview of the potential strategies for NK cell-based immunotherapy for acute myeloid leukemia

Sinha C, Cunningham LC.
Pediatr Blood Cancer. 63(12): 2078-2085, 2016. [ Journal Article ]

Harnessing formulation and clinical pharmacology knowledge for efficient pediatric drug development: Overview and discussions from M-CERSI pediatric formulation workshop 2019

Khong YM, Liu J, Cook J, Purohit V, Thompson K, Mehrotra S, Cheung SYA, Hay JL, Fletcher EP, Wang J, Sachs HC, Zhu H, Siddiqui A, Cunningham L, Selen A.
European Journal of Pharmaceutics and Biopharmaceutics. 164: 66-74, 2021.
Full-Text Article
[ Journal Article ]

Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1-CBFβ interaction

Cunningham L, Finckbeiner S, Hyde RK, Southall N, Marugan J, Yedavalli VR, Dehdashti SJ, Reinhold WC, Alemu L, Zhao L, Yeh JR, Sood R, Pommier Y, Austin CP, Jeang KT, Zheng W, Liu P.
Proceedings of the National Academy of Sciences. 109 (36): 14592-14597, 2012.
Full-Text Article
[ Journal Article ]